Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANAPTYSBIO, INC.

(ANAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Analyst Recommendations on ANAPTYSBIO, INC.
11/05Wedbush Adjusts Price Target for AnaptysBio to $35 From $32, Maintains Neutral Rating
MT
10/26Wedbush Lifts AnaptysBio's Price Target to $32 From $25 on Dostarlimab Royalty Agreemen..
MT
10/05ANAPTYSBIO : Releases Data From Phase 2 GALLOP Trial For Imsidolimab Drug, Wedbush Says; K..
MT
08/18ANAPTYSBIO : Wedbush Lifts AnaptysBio's Price Target to $25 From $20 on Dostarlimab Update..
MT
06/22ANAPTYSBIO : HC Wainwright Initiates AnaptysBio at Buy Rating With $43 Price Target
MT
05/21ANAPTYSBIO : UBS Starts AnaptysBio at Neutral with $29 Price Target
MT
03/16ANAPTYSBIO : Truist Securities Upgrades AnaptysBio to Buy From Hold
MT
03/09ANAPTYSBIO : Wedbush Cuts AnaptysBio to Neutral From Outperform, PT to $19 From $35 on Ims..
MT
02/11ANAPTYSBIO : JPMorgan Upgrades AnaptysBio to Overweight From Underweight; Price Target is ..
MT
Upcoming event on ANAPTYSBIO, INC.
03/07/22